89,117 Shares in Emergent Biosolutions Inc. $EBS Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new stake in Emergent Biosolutions Inc. (NYSE:EBS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 89,117 shares of the biopharmaceutical company’s stock, valued at approximately $747,000. Sanctuary Advisors LLC owned 0.17% of Emergent Biosolutions at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EBS. BlackRock Inc. bought a new stake in Emergent Biosolutions in the second quarter valued at approximately $39,525,000. Dimensional Fund Advisors LP raised its holdings in Emergent Biosolutions by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after purchasing an additional 504,553 shares during the last quarter. State Street Corp raised its holdings in Emergent Biosolutions by 10.2% during the 4th quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock worth $33,327,000 after purchasing an additional 250,616 shares during the last quarter. Millennium Management LLC lifted its position in shares of Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after purchasing an additional 1,020,582 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Emergent Biosolutions by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock worth $20,010,000 after purchasing an additional 237,153 shares during the period. 78.40% of the stock is currently owned by institutional investors.

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. started coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They set an “underweight” rating for the company. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Price Performance

Shares of EBS opened at $5.92 on Friday. The firm has a market cap of $303.52 million, a PE ratio of -1.67 and a beta of 2.35. Emergent Biosolutions Inc. has a 52-week low of $4.36 and a 52-week high of $14.06. The business’s 50 day moving average price is $6.88 and its two-hundred day moving average price is $8.08. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.68. The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, equities analysts anticipate that Emergent Biosolutions Inc. will post -4.61 EPS for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.